Jan 05, 2026
A Look Into Cummins Inc’s Price Over Earnings

In the current session, the stock is trading at $523.50, after a 0.28% spike. Over the past month, Cummins Inc. (NYSE:CMI) stock increased by 5.95%, and in the past year, by 47.21%. With performance like this, long-term shareholders are optimistic…

Jan 05, 2026
Stock Of The Day: Is The Chevron Rally About To End?

Chevron Corp (NYSE:CVX) shares are trading higher on Monday. Investors are excited about the company's future prospects in Venezuela now that President Nicolás Maduro has been forced out of office. • Chevron stock is showing exceptional strength. What’s driving CVX stock…

Jan 05, 2026
Amazon Launches Alexa+ Website To Rival ChatGPT

Amazon.com Inc (NASDAQ:AMZN) is expanding Alexa+ to the web as it ramps up competition with leading artificial intelligence chatbots. On Monday, Amazon launched Alexa.com, a browser-based experience that allows users to interact with Alexa+ directly from a desktop or laptop.…

Jan 05, 2026
Bitmine Adds 32,977 ETH As BMNR Sits At Critical $34 Support

Bitmine Immersion Technologies Inc. (NYSE:BMNR) bought 32,977 Ethereum (CRYPTO: ETH) last week to push total holdings to 4.144 million ETH worth $13.2 billion, with the BMNR stock holding at a critical support level. Bitmine Now Owns 3.43% Of ETH Supply…

Jan 05, 2026
Qualcomm Turns ‘Physical AI’ From Buzzword Into Reality

At CES 2026, Qualcomm Inc. (NASDAQ:QCOM) aggressively positioned itself as the central architect of the “connected edge,” providing full-stack ecosystems for IoT, robotics, and automotive sectors. Unifying IoT and Next-Gen Robotics Qualcomm is consolidating the fragmented Internet of Things market…

Jan 05, 2026
P/E Ratio Insights for Carnival

In the current market session, Carnival Inc. (NYSE:CUK) stock price is at $30.22, after a 1.50% drop. However, over the past month, the company's stock went up by 32.25%, and in the past year, by 44.09%. Shareholders might be interested…

Jan 05, 2026
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer

Incyte Corporation (NASDAQ:INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The trial evaluated tafasitamab and lenalidomide in…